Zurich, Switzerland

Michela Silacci-Melkko



 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 41(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: A Spotlight on Inventor Michela Silacci-Melkko

Introduction

Michela Silacci-Melkko is an innovative inventor based in Zurich, Switzerland. She has made significant contributions to the field of immunology, particularly through her work on immunoconjugates. As a dedicated researcher, she has a singular patent to her name, reflecting her commitment to advancing medical science.

Latest Patents

Michela’s notable patent is centered around "Targeted Immunoconjugates." This invention focuses on immunoconjugates that comprise at least one single-chain effector moiety along with two or more antigen-binding moieties. Furthermore, her patent encompasses nucleic acid molecules encoding such immunoconjugates, as well as the vectors and host cells necessary for their production. The methods of utilizing these immunoconjugates for treating diseases also form a crucial aspect of her patent.

Career Highlights

She is currently associated with Roche Glycart AG, a company renowned for its advancements in biopharmaceuticals. Michela's role at Roche Glycart has allowed her to work at the cutting edge of medical innovation, contributing to vital research that has the potential to shape future treatments.

Collaborations

During her career, Michela has collaborated with esteemed colleagues including Ekkehard Mössner and Ralf Jörg Hosse. These collaborations foster an environment of shared knowledge and collective innovation, vital for the progression of their research in the biopharmaceutical field.

Conclusion

Michela Silacci-Melkko exemplifies the spirit of innovation and dedication within the realm of scientific research. Her patented work on targeted immunoconjugates not only showcases her inventiveness but also holds promise for significant advancements in disease treatment. Through her efforts at Roche Glycart AG and her collaborations with fellow researchers, she continues to make impactful contributions to the scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…